First primary care trial supports FeNO-guided asthma

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 11, 2013 at 4:15 AM

First primary care trial supports FeNO-guided asthma treatment

SOLNA, Sweden – 11 October, 2013 - Aerocrine AB (OMX Nordic Exchange: AERO) – A new randomised clinical trial shows lower incidence of asthma exacerbations and increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti -inflammatory treatment. The study has been published on the website of Journal of Allergy and Clinical Immunology: In Practice (http://www.jaci -inpractice.org/article/S2213-2198(13)00352-8/abstract). A total of 187 non-smoking asthma patients (18-64 years) with perennial allergy and on regular inhaled corticosteroid (ICS) treatment were recruited at 17 primary health care centres in Sweden, randomly assigned to two groups and followed for one year. One group was treated with standard of care whereas treatment of the patients in the other group were guided by FeNO. Aerocrine’s patented FeNO test, with the NIOX® MINO® device was used in the study. In the standard of care group FeNO was blinded for both patient and physician. “FeNO-guided anti-inflammatory treatment enabled the physicians to optimize the treatment with for example inhaled corticosteroids so that both over- and undertreatment can be avoided. This may be a useful tool in long-term management of patients with asthma”, says Dr Jörgen Syk, General Practitioner at Runby primary care clinic, Stockholm, Sweden and being the principal investigator in the study. Overall, FeNO-guided management resulted in improved asthma symptom control and reduced exacerbation frequency in adults with asthma. The FeNO-guided group reported almost 50% fewer asthma exacerbations without an increase in the used average dose of corticosteroids. Although there was no difference in perceived quality of life (which was the primary endpoint of the study) between the groups, the FeNO-guided group reported fewer symptoms than the group following standard of care treatment. “This is the third major, well controlled, blinded trial* to confirm that FeNO is a useful biomarker for the management of asthma by reducing exacerbations and managing the utilization of the appropriate medication at the correct time. This information further substantiates and strengthens the clinical evidence behind the American Thoracic Society (ATS) guidelines. These guidelines are also endorsed by American College of Allergy, Asthma and Immunology (ACAAI) and the American Academy of Allergy, Asthma and Immunology (AAAAI), said Scott Myers, CEO Aerocrine AB. Asthma is a chronic inflammatory airways disease that is characterized by symptoms including wheezing and difficulty in breathing. Asthma is one of the world’s most common and costly diseases; it affects 8-10 per cent of the population and is associated with enormous healthcare expenditures that include direct and indirect costs. The disease has no cure, and proper diagnosis and management is crucial for improved quality of life for the patients. FeNO measurement enables physicians to better assess and manage patients with allergic airway inflammation. For more information, contact: Scott Myers, Chief Executive Officer, Aerocrine, Phone: +46 768 788 379 Dr Kathy Rickard, Chief Medical Officer Aerocrine, Phone : +1 919 749 6708 About Aerocrine Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO®, which enables fast and reliable point-of-care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow -up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com. Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 10 am on October 11 2013.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Laars Welcomes Women in Manufacturing to Facility Tour

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...